Literature DB >> 1670640

Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.

S Jung1, H J Schluesener.   

Abstract

P21ras proteins are thought to play an important role in cell proliferation and differentiation. Single nucleotide mutations in the encoding cellular proto-oncogenes often result in p21ras proteins with transforming activity. Such activated ras oncogenes have been demonstrated in a variety of human malignancies and also in preneoplastic changes. Using a synthetic peptide corresponding to amino acids 5-16 of mutated p21ras proteins with an exchange of the normal glycine at position 12 by valine, it is shown here that human CD4+ T cells specifically recognize the mutated protein sequence and can be generated as antigen-specific T lymphocyte lines. The fact that these T lines did not crossreact to the sequence of normal p21ras proteins offers new perspectives for specific immunotherapy of human malignancies and even precancerous lesions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670640      PMCID: PMC2118763          DOI: 10.1084/jem.173.1.273

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.

Authors:  K Forrester; C Almoguera; K Han; W E Grizzle; M Perucho
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

2.  Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells.

Authors:  C Lurquin; A Van Pel; B Mariamé; E De Plaen; J P Szikora; C Janssens; M J Reddehase; J Lejeune; T Boon
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

3.  Cytotoxic T lymphocytes against a soluble protein.

Authors:  U D Staerz; H Karasuyama; A M Garner
Journal:  Nature       Date:  1987 Oct 1-7       Impact factor: 49.962

4.  Cytotoxic T lymphocytes recognize influenza haemagglutinin that lacks a signal sequence.

Authors:  A R Townsend; J Bastin; K Gould; G G Brownlee
Journal:  Nature       Date:  1986 Dec 11-17       Impact factor: 49.962

5.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

6.  A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.

Authors:  H Hirai; Y Kobayashi; H Mano; K Hagiwara; Y Maru; M Omine; H Mizoguchi; J Nishida; F Takaku
Journal:  Nature       Date:  1987 Jun 4-10       Impact factor: 49.962

7.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

Authors:  C Almoguera; D Shibata; K Forrester; J Martin; N Arnheim; M Perucho
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

8.  Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.

Authors:  P L Ward; H Koeppen; T Hurteau; H Schreiber
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

9.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

10.  Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells.

Authors:  C Van Waes; J L Urban; J L Rothstein; P L Ward; H Schreiber
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more
  25 in total

Review 1.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 2.  Beyond RAS and BRAF: a target rich disease that is ripe for picking.

Authors:  Tyler Friedrich; Stephen Leong; Christopher H Lieu
Journal:  J Gastrointest Oncol       Date:  2016-10

Review 3.  Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.

Authors:  Pierpaolo Correale; Maria Grazia Cusi; Lucia Micheli; Cristina Nencini; Maria Teresa Del Vecchio; Francesco Torino; Angelo Aquino; Enzo Bonmassar; Guido Francini; Giorgio Giorgi
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

4.  Major histocompatibility complex-restricted recognition of autologous chronic lymphocytic leukemia by tumor-specific T cells.

Authors:  W Sherman; Z Liu; G Inghirami; E F Reed; P E Harris; N M Suciu-Foca
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

5.  Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.

Authors:  P Escobar; Z Yu; A Terskikh; N Holmes; G Corradin; J P Mach; F Healy
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 6.  Tumor antigens discovery: perspectives for cancer therapy.

Authors:  R F Wang
Journal:  Mol Med       Date:  1997-11       Impact factor: 6.354

7.  T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits.

Authors:  A A Manfredi; M P Protti; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.

Authors:  T Gedde-Dahl; E Nilsen; E Thorsby; G Gaudernack
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

Review 9.  Therapeutic Approaches to RAS Mutation.

Authors:  Aaron J Scott; Christopher H Lieu; Wells A Messersmith
Journal:  Cancer J       Date:  2016 May-Jun       Impact factor: 3.360

10.  CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13-->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation.

Authors:  B Fossum; A C Olsen; E Thorsby; G Gaudernack
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.